Management of Dyslipidemia in Adult Type 2 Diabetes Patients in India

N/ACompletedNCT01292018

AstraZeneca5,400 enrolled

Overview

The purpose of study to assess the control of dyslipidemia in the Indian diabetic population treated with any hypolipidemic agent.

Study Type

OBSERVATIONAL

Enrollment

5,400

Conditions

Dyslipidemia Type 2 Diabetes Mellitus

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult who is a known Type 2 diabetic as per the ADA 2010 criteria OR controlled diabetic (taking any antidiabetic medication) * Patients in the study will have been on lipid lowering drugs at a stable dose for the last three months before the designated study visit. Exclusion Criteria: * Type 1 diabetic patients * Patients with a history of hepatic or renal diseases * Hypertension due to organic diseases

Outcomes

Primary Outcomes

Proportion of type 2 diabetic dyslipidemia patients achieving the target LDL goal according to ADA 2010. These patients should be on stable dose of Lipid Lowering Drugs(LDL) for at least 3 months

Secondary Outcomes

Proportion of dyslipidemia control rate according to american diabetes Association (ADA) 2010 criteria by age and gender

Control of dyslipidemia by Lipid Lowering Drugs (LLDs) drugs alone or combination

Control of dyslipidemia by all commercial available brands hypolipidemics drugs

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.